公开(公告)号：US20220380937A1

公开(公告)日：2022-12-01

申请号：US17775198

申请日：2020-11-06

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Yi XING ,  Robert PRINS ,  Yang PAN ,  Alexander H. LEE

IPC: C40B40/08 ,  A61K35/15 ,  A61K35/17 ,  A61K35/28 ,  A61K35/545 ,  C07K14/725 ,  G16B30/10

Abstract: Methods and processes to identify neoplastic tissue antigens derived from alternative splicing (AS) are described, in accordance with various embodiments of the invention. Also described are novel tumor antigens that are useful as targets in various immunotherapeutic approaches to treating brain cancer as well as novel engineered T cell Receptors (TCRs) and chimeric antigen receptors (CARs) that target these antigenic peptides.

公开(公告)号：US20240182518A1

公开(公告)日：2024-06-06

申请号：US17760479

申请日：2021-02-12

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Yi XING ,  Owen WITTE ,  John PHILLIPS ,  Yang PAN

IPC: C07K7/02 ,  A61K39/00

CPC classification number: C07K7/02 ,  A61K39/00 ,  C07K2319/40 ,  C07K2319/92

Abstract: Methods and processes to identify neoplastic tissue antigens derived from alternative splicing (AS) are described, in accordance with various embodiments of the invention. Also described are novel tumor antigens that are useful as targets in various immunotherapeutic approaches to treating cancer as well as novel engineered T cell Receptors (TCRs) and chimeric antigen receptors (CARs) that target these antigenic peptides.

公开(公告)号：US20160264934A1

公开(公告)日：2016-09-15

申请号：US15067780

申请日：2016-03-11

Applicant: THE GENERAL HOSPITAL CORPORATION ,  The Regents of the University of California

Inventor： Cosmas GIALLOURAKIS ,  Alan C. MULLEN ,  Yi XING

IPC: C12N5/0735 ,  A01N1/02 ,  C12Q1/68 ,  G01N33/573 ,  C12N5/077 ,  C12N5/0793

CPC classification number: C12N5/0606 ,  A01N1/0226 ,  C12N5/0619 ,  C12N5/0657 ,  C12N2501/72 ,  C12N2506/02 ,  C12Q1/6888 ,  C12Q2600/158 ,  C12Y201/01 ,  C12Y201/01062 ,  G01N33/5308 ,  G01N33/573 ,  G01N2440/12

Abstract: The present invention generally relates to methods, assays and kits to maintain a human stem cell population in an undifferentiated state by inhibiting the expression or function of METTL3 and/or METTL4, and m6A fingerprint methods, assays, arrays and kits to assess the cell state of a human stem cell population by assessing m6A levels (e.g. m6A peak intensities) of a set of target genes disclosed herein to determine if the stem cell is in an undifferentiated or differentiated state.

Abstract translation: 本发明一般涉及通过抑制METTL3和/或METTL4的表达或功能以及m6A指纹方法，测定，阵列和试剂盒来维持未分化状态的人类干细胞群体以评估细胞状态的方法，测定和试剂盒 通过评估本文公开的一组靶基因的m6A水平（例如m6A峰强度）来确定干细胞是否处于未分化或分化状态。